Thera-SAbDab

ETARACIZUMAB

>   Structural Summary
TherapeuticEtaracizumab
TargetITGAV_ITGB3
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedApplied Molecular Evolution, MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedColorectal cancer, Malignant melanoma, Prostate cancer, Psoriasis, Rheumatoid arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]